(Q33392468)

26 July 2017

title

A phase I study of temsirolimus and metformin in advanced solid tumours (English)

1 reference

26 July 2017

1 reference

Mary J MacKenzie

1

1 reference

26 July 2017

Scott Ernst

series ordinal

2

1 reference

26 July 2017

Craig Johnson

series ordinal

3

1 reference

26 July 2017

Eric Winquist

series ordinal

4

1 reference

26 July 2017

publication date

27 October 2010

1 reference

Investigational New Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

30

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

647-652

1 reference

mTOR and cancer: insights into a complex relationship

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Metformin: taking away the candy for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9570-8

Pharmacogenetics of metformin response: a step in the path toward personalized medicine

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20978924

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-010-9570-8

1 reference

Dimensions Publication ID

26 July 2017

1030064834

0 references

1 reference